After months of debate and uncertainty the World Health Organization has released a proposal for naming biosimilars which are designed to emulate brandname biologics and are forecast to save untold billions of dollars in health care costs in coming years At issue is whether biosimilars should be given the same International NonProprietary Name or INN as brandname biologics The global INN system is overseen by the WHO which has held several meetings to resolve the question And a key point of contention is whether different INNs would hamper substitution needed for lowering health care costs and this has divided the pharmaceutical industry